Open AccessRemdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
Author(s) -
Al Bishawi Ahmad,
Abdel Hadi Hamad,
Elmekaty Eman,
Al Samawi Musaed,
Nair Arun,
Abou Kamar Mohammed,
Al Maslamani Muna,
Abdelmajid Alaaeldin
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5467
Subject(s) - medicine , covid-19 , intensive care medicine , pneumonia , kidney disease , authorization , disease , virology , infectious disease (medical specialty) , outbreak , computer security , computer science
Abstract Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.